W1020

W146 hydrate

≥98% (HPLC)

• Sinônimo(s): ML056, R-3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid hydrate, [(3R)-3-amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid
• Fórmula empírica (Notação de Hill): C₁₆H₂₇N₂O₄P · xH₂O
• Número CAS: 909725-61-7
• Peso molecular: 342.37 (anhydrous basis)
• Número MDL: MFCD16875441
• Código UNSPSC: 12352211
• ID de substância PubChem: 329830425
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• forma: powder
• cor: off-white
• solubilidade: methanol: soluble (with 0.1% TFA)
• originador: Novartis
• temperatura de armazenamento: 2-8°C
• cadeia de caracteres SMILES: O.CCCCCCc1cccc(NC(=O)[C@H](N)CCP(O)(O)=O)c1
• InChI: 1S/C16H27N2O4P.H2O/c1-2-3-4-5-7-13-8-6-9-14(12-13)18-16(19)15(17)10-11-23(20,21)22;/h6,8-9,12,15H,2-5,7,10-11,17H2,1H3,(H,18,19)(H2,20,21,22);1H2/t15-;/m1./s1
• chave InChI: DQKSZHVSROOTFY-XFULWGLBSA-N

Descrição

Descrição geral

W146 hydrate functions as an orthosteric antagonist. It is associated with blood lymphopenia and lung edema in mice.

Aplicação

W146 hydrate has been used to assess vascular permeability in mice.

Ações bioquímicas/fisiológicas

Potent S1P(1) competitive antagonist; Ki = 10-77 nM.

Características e benefícios

This compound is featured on the Lysophospholipid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informações de segurança

• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable